跳至主要内容
临床试验/NL-OMON48248
NL-OMON48248已完成4 期

Pragmatic trial baricitinib versus First biological in *Tight Control* Patients suffering from Rheumatoid Arthritis (PERFECT) - PERFECT

Overige Centra0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Clinical diagnosis of RA
  • Active disease defined a s DAS28> 3.2
  • Former treatment according to T2T prin ciples, at the discretion of the
  • attending rheumatologist, i.e. past treatment decisions informed by disease
  • activity measurements
  • Previous use of at least one csDMARD

排除标准

  • Disease duration >5 years
  • Previous treatment with any biological DMARD or tsDMARD
  • Contraindication for either TNFi or JAK inhibitor
  • Latent or active tuberculosis
  • Active or recurrent infections
  • 3x upper limit of normal ALAT
  • GFR < 30 ml/min.
  • Failure to provide written informed consent

研究者

发起方
Overige Centra

相似试验